US court invalidates Velcade patent after Sandoz challenge
Sandoz, Allergan and Accord Healthcare have demonstrated “clear and convincing” evidence that a patent owned by Millennium Pharmaceuticals and used in its Velcade (bortezomib) cancer treatment drug is invalid, according to a US court ruling.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
